Anti-angiogenic therapy in the treatment of advanced renal cell cancer
- 28 February 2007
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 33 (1), 1-8
- https://doi.org/10.1016/j.ctrv.2006.08.003
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Immunotherapy for advanced renal cell cancerPublished by Wiley ,2004
- Overproduction of Vascular Endothelial Growth Factor Related to von Hippel-Lindau Tumor Suppressor Gene Mutations and Hypoxia-Inducible Factor-1α Expression in Renal Cell Carcinomas.Journal of Urology, 2003
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and TherapyJournal of Clinical Oncology, 2002
- Vascular endothelial growth factor overexpression is correlated with von Hippel‐Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinomaCancer, 2002
- PROGNOSTIC SIGNIFICANCE OF THE 1997 TNM CLASSIFICATION OF RENAL CELL CARCINOMAJournal of Urology, 1999
- The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysisNature, 1999
- The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.Molecular Biology of the Cell, 1993
- Identification of the von Hippel-Lindau Disease Tumor Suppressor GeneScience, 1993